Skip to content

News

27th October 2026

Merakris Advances Potentially Pivotal MTX-001 Phase 2/3 Strategy Following FDA Pre-IND Meeting

8th September 2026

Merakris Therapeutics Launches Patent-Pending AmnioSurge™ With 360 Medical, Opening New Surgical Revenue Channel

21st July 2026

Merakris Therapeutics Awarded NIH Direct-to-Phase II SBIR Grant to Advance MTX-001 for Diabetic Foot Ulcers

17th June 2026

Merakris Therapeutics Awarded U.S. Department of Veterans Affairs Federal Supply Schedule Contract, Expanding Federal Market Access for Dermacyte® AC Matrix Amniotic Membrane Allograft

2nd June 2026

FDA Grants Fast Track Designation to Merakris’ MTX-001, Opening Potential Accelerated Path to Market for Venous Leg Ulcer Therapy

Top